AXSOME THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
AXSOME THERAPEUTICS, INC. (AXSM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of -$6.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2026-06-30 was -$3.05M.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2026-03-31 was -$3.26M.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-12-31 was -$2.94M.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-09-30 was -$2.51M.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2025 was -$9.94M.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2024 was -$7.87M.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2023 was -$6.21M.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2022 was -$2.44M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$6.31M 10-Q · filed 2026-08-10 | -$9.26M derived: sum of 3 quarters · filed 2026-08-10 | -$11.76M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$3.26M 10-Q · filed 2026-05-04 | -$6.21M derived: sum of 2 quarters · filed 2026-05-04 | -$8.71M derived: sum of 3 quarters · filed 2026-05-04 | -$10.92M derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | -$2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$5.45M derived: sum of 2 quarters · filed 2026-02-23 | -$7.66M derived: sum of 3 quarters · filed 2026-02-23 | -$9.94M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$2.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$4.71M derived: sum of 2 quarters · filed 2025-11-03 | -$7.00M 10-Q · filed 2025-11-03 | -$9.13M derived: sum of 4 quarters · filed 2025-11-03 |
| 2025-06-30 | -$2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$4.49M 10-Q · filed 2025-08-04 | -$6.62M derived: sum of 3 quarters · filed 2025-08-04 | -$8.56M derived: sum of 4 quarters · filed 2025-08-04 |
| 2025-03-31 | -$2.29M 10-Q · filed 2025-05-05 | -$4.42M derived: sum of 2 quarters · filed 2025-05-05 | -$6.36M derived: sum of 3 quarters · filed 2025-05-05 | -$8.24M derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | -$2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$4.07M derived: sum of 2 quarters · filed 2025-02-18 | -$5.96M derived: sum of 3 quarters · filed 2025-02-18 | -$7.87M 10-K · filed 2025-02-18 |
| 2024-09-30 | -$1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$3.83M derived: sum of 2 quarters · filed 2024-11-12 | -$5.74M 10-Q · filed 2024-11-12 | -$7.46M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | -$1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$3.79M 10-Q · filed 2024-08-05 | -$5.52M derived: sum of 3 quarters · filed 2024-08-05 | -$6.96M derived: sum of 4 quarters · filed 2024-08-05 |
| 2024-03-31 | -$1.91M 10-Q · filed 2024-05-06 | -$3.63M derived: sum of 2 quarters · filed 2024-05-06 | -$5.07M derived: sum of 3 quarters · filed 2024-05-06 | -$6.38M derived: sum of 4 quarters · filed 2024-05-06 |
| 2023-12-31 | -$1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | -$3.16M derived: sum of 2 quarters · filed 2024-02-23 | -$4.47M derived: sum of 3 quarters · filed 2024-02-23 | -$6.21M 10-K · filed 2024-02-23 |
| 2023-09-30 | -$1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$2.75M derived: sum of 2 quarters · filed 2023-11-06 | -$4.49M 10-Q · filed 2023-11-06 | -$6.09M derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | -$1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$3.05M 10-Q · filed 2023-08-07 | -$4.65M derived: sum of 3 quarters · filed 2023-08-07 | |
| 2023-03-31 | -$1.74M 10-Q · filed 2023-05-09 | -$3.34M derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2022-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$2.44M 10-K · filed 2023-02-28 | ||
| 2022-09-30 | -$837.88K 10-Q · filed 2022-11-07 | |||
| 2015-12-31 | $244.77K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $1.34M derived: sum of 2 quarters · filed 2017-03-07 | $1.34M 10-K · filed 2017-03-07 | |
| 2015-09-30 | $1.09M 10-Q · filed 2016-11-14 | $1.09M 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |